Sai Parenteral's Limited reported a standalone net profit of ₹88.75 million for the quarter ended June 30, 2026, marking a 975% year-on-year increase from ₹8.25 million in Q1FY26. This significant turnaround was driven by a 175% surge in revenue from operations to ₹527.79 million, compared to ₹192.00 million in the corresponding period of the previous fiscal year. The strong top-line growth outpaced expense increases, leading to a substantial expansion in profitability metrics for the quarter.

The Board of Directors approved these unaudited financial results on August 11, 2026. Statutory Auditors R. Kabra & Co. LLP issued an unmodified limited review conclusion on the standalone and consolidated financial statements. The company’s equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on April 2, 2026; consequently, comparative data for Q1FY26 is presented as unaudited information to facilitate comparability, as the company was not previously required to publish quarterly results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

On a consolidated basis, net profit after tax stood at ₹79.23 million, up from ₹14.15 million in Q1FY26. Consolidated revenue from operations reached ₹1,786.72 million, a significant increase from ₹333.91 million in the prior year period. Total comprehensive income for the consolidated group was ₹79.23 million. The primary driver of this growth appears to be the integration and performance of its subsidiaries, particularly in the international markets, although specific segment-wise disclosures were not provided as management evaluates performance based on the sole reportable segment of branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) products.

Beyond financial performance, the Board approved strategic shifts in capital allocation. The company will utilize ₹838.34 million, originally earmarked for upgrading Unit I and Unit II manufacturing facilities, to acquire a 60% equity stake in Saicriti Pharma Private Limited. This acquisition involves a state-of-the-art critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad, with a total estimated development cost of ₹2,149.60 million. Additionally, ₹180.23 million allocated for establishing a new Research & Development Centre will be redirected to acquire a 60% stake in Prathyak Laboratories Private Limited, an established pharmaceutical R&D platform with a portfolio of 124 products under development. Both acquisitions are subject to shareholder approval and aim to achieve strategic objectives with lower execution risk and shorter timeframes.

Key Financial Metrics (Standalone)

Key Financial Metrics (Consolidated)

What the Numbers Show

The divergence between standalone and consolidated performance highlights the weight of international subsidiaries in the group’s overall profile. While standalone revenue grew by 175%, consolidated revenue surged by 435%, indicating that foreign operations contributed disproportionately to the top-line expansion. However, consolidated net profit grew by 460%, slightly outpacing the standalone growth rate of 975% when adjusted for base effects, suggesting improving efficiency or scale in the consolidated entities. Notably, Noumed Pharmaceuticals Pty Limited, a step-down subsidiary, reported a total revenue of ₹1,037.09 million but incurred a loss of ₹89.53 million, which may be impacting the consolidated bottom line despite the overall profit growth. The company also announced the incorporation of a new wholly-owned subsidiary in the United States, further signaling its intent to deepen its US market presence.

Corporate Governance Changes

The Board also addressed several governance matters. Anil Kumar Karusala was re-appointed as Director retiring by rotation and proposed for re-appointment as Managing Director for three years effective January 1, 2027. Vijitha Gorrepati was proposed for re-appointment as Whole-Time Director for three years from January 1, 2027. Kunal Kakumanu was appointed as Additional and Executive Director for three years effective August 11, 2026. Conversely, Aruna Karusala resigned as Non-Executive Director effective August 11, 2026, citing personal reasons. Shivali Aggarwal resigned as Company Secretary and Compliance Officer, with her resignation effective on or before October 12, 2026. The Annual General Meeting for FY25-26 is scheduled for September 10, 2026.

Sai Parenterals Limited has appointed new auditors for the financial year 2026-27 and authorized its Managing Director to explore strategic growth opportunities. The decisions were taken during a board meeting held on July 06, 2026, at the company's registered office. These appointments are subject to necessary regulatory approvals and shareholder consent where applicable.

Auditor Appointments

The board approved the appointment of M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, as Secretarial Auditors for a period of five financial years, from 2026-27 to 2030-31. This appointment is subject to the approval of shareholders. For the financial year 2026-27, the board appointed M/s. NSVR & Associates LLP, Chartered Accountants, as Internal Auditors and M/s. Sai Krishna & Associates, Cost Accountants, as Cost Auditors.

Strategic Authorization

In addition to the auditor appointments, the board authorized Mr. Anil Kumar Karusala, Chairman & Managing Director, to identify, evaluate, and explore suitable organic and inorganic growth opportunities. This mandate covers the existing line of business as well as other strategic areas deemed beneficial to the company.

Appointment Details